Alimta

... Lilly pledges $12.5 million to further cancer research MARKETPLACE: Classifieds Dana Knight AP Business AP Technology Sports Entertainment Indiana Living Obituaries Weather | Traffic CustomerServices SubscriberServices INtake Community Fact Files MessageBoards Multimedia/Photos Newsletters Star Source Send us yournews tips, ideas Star Links Links mentionedin The Star Star Headlines Get RSS feedof latest news 7 days Archive Lilly pledges $12.5 million to further cancer research By Jeff Swiatek April 13, 2005 Eli Lilly and Co.

has pledged a follow-up donation of $12.5 million over the next five years to the Damon Runyon Cancer Research Foundation.

The newest grant, to be announced today, comes on the heels of a $15 million, five-year grant Lilly made in 2000 to the same New York foundation.

The money supports a foundation program to promote cancer research by giving $1 million grants each year to five young cancer researchers.

With the grants, Lilly is trying to reverse a slow slide in cancer research in the United States, where the number of physicians engaged in clinical research has dropped by 50 percent over the past two decades, said Lilly spokesman Gregory L.

Clarke.

"We're left facing a tremendous gap in the developmen...

... Health Products Research Reports on 2004 Promotional Activities to Hematology and Oncology Specialists Health Products Research Reports on 2004 Promotional Activities to Hematology and Oncology Specialists * Aranesp(R) Gives Amgen Greatest Share of Voice Among Hematologists and Oncologists * Pharmaceutical Sales Force Promotion to Hematology and Oncology Specialists Increased 4% in 2004 * Aranesp(R) (Amgen), Taxotere(R) (Sanofi Aventis) and Procrit(R) (Ortho Biotech) Ranked as Top 3 Products with Hematologists and Oncologists in 2004 * 6 Products Enter Top 20 Ranking for the First Time WHITEHOUSE, N.J., April 7 /PRNewswire-FirstCall/ - Health Products Research, Inc.(R) (HPR(R)), a division of Ventiv Health, Inc.

(Nasdaq: VTIV), released 2004 market information on pharmaceutical sales force promotional activities to Hematology and Oncology specialists across the United States.

HPR generates market data from its Metropolitan Area Promotional Audit (MPA), a monthly service that provides quantitative and qualitative insights and real-time data from pharmaceutical/healthcare company promotional activities and sales force structure.

Key findings from the 2004 Hematology and Oncology specialists MPA report include: * Nationwide, pharmaceutical sales force promotion to Hematology and Oncology specialists increased 4% in 2004 compared to the prior year, bolstered by sales force promotion behind six products entering the top 20 in 2004, as well as increased prom...

... OSI Catches Tarceva Bid Reinvention Time for PfizerBiogen Idec Revises EarningsGenentech Gains on Novartis, Schering Setback Quotes Site Search Advanced Search Check out our brand new technology product now TheStreet.com Technology Report 30-DAY FREE TRIAL Jim Cramer's top stock picksStocks Under $10 - View our favorite stock picks!

Stock News : Biotech/Pharmaceuticals OSI Catches Tarceva Bid By Althea ChangStaff Reporter 4/5/2005 5:18 PM EDT Shares of OSI Pharmaceuticals (OSIP:Nasdaq - commentary - research) rose Tuesday on the news that its partner, Genentech (DNA:NYSE - commentary - research), will increase wholesale prices of the cancer drug Tarceva.

OSI shares rose $2.86, or 7.2%, to $42.67.

Genentech shares rose 73 cents, or 1.3% to $56.63.

OSI shares were on a steady decline in recent months, as analysts drastically lowered OSI price targets and sales projections blaming competition from Eli Lilly's (LLY:NYSE - commentary - research) cancer drug Tarceva prescriptions have been lower than expected.

Last month, Jim Birchenough of Lehman Brothers lowered his price target for OSI to $58 from $80 and reduced 2006 sales estimates to $336 million from $396 million and 2007 sales to $520 million from $600 million.

His price targets last summer were as much as $120.

When Genentech revealed last month that trials of its biologic drug Avastin combined with traditional chemotherapy drugs prolonge...